About Vimta
Vimta is a publicly listed company based in Hyderabad (India) founded in 1984. It operates as a contract research and clinical services are provided to pharmaceutical firms. The company has 1,310 employees. Its website vimta.com draws about 294 thousand monthly visits. Its Indian entity Vimta Labs Limited reported revenue of ₹416 Cr. Vimta offers products and services including cGMP Laboratory Service, Preclinical Research, Clinical Research, and Food Testing Services. Its focus areas include Biopharma Outsourcing, CRO and Diversified. Similar companies include Charles River Laboratories, Cytel, LabCorp, Precision Medicine Group and Frontage Laboratories and 5 more; 7 of its 10 listed similar companies have raised funding.
Company details
Vimta Labs was founded in 1984 in Hyderabad, India, functioning as a contract research organization for pharmaceutical and biotechnology sectors. Analytical services, clinical research, preclinical studies, genomics, proteomics, and BABE testing are delivered to global clients. Operations involve 565 scientists working in chemistry, pharmacy, medicine, microbiology, molecular biology, and informatics.
- Annual Revenue₹416 Cr
FY 2026 · +20% YoY
- Net Profit₹77.51 Cr
FY 2026 · 19% margin
- EBITDA₹149 Cr
FY 2026 · 36% margin
- Latest Funding Round$17M (USD), Post-IPO
Jun 2006
- Employee Count1,310
Associated legal entities of Vimta
Vimta operates through Vimta Labs Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Vimta Labs Limited Listed CIN L24110TG1990PLC011977 | Active | 16 Nov 1990 | – | ₹416 Cr | 1,456 | 10 | View details |
Products & Services of Vimta
Vimta offers a comprehensive portfolio of products and services, including cGMP Laboratory Service, Preclinical Research, Clinical Research, and Food Testing Services.
Provides compliant testing for pharmaceutical products and safety
Conducts studies for drug development and efficacy testing
Offers trials for biologics and biosimilars evaluation
Ensures quality and safety in food and water analysis
Apps and channels of Vimta
its YouTube channel Vimta Labs Ltd has 659 subscribers and 12 videos.
Videos from Vimta
The most watched videos on Vimta's YouTube channel, Vimta Labs Ltd (659 subscribers). Click a video to play it here.
More on Vimta Labs Ltd.
Funding Insights of Vimta
- Total Rounds 1
- Last Round Post-IPO — $17M
- First Round $17M
(Jun 2006)
All 1 funding rounds of Vimta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2006 | $17M | Post-IPO | – | – | – |
Board of directors of Vimta Labs Limited (Vimta)
Vimta Labs Limited is the primary company behind Vimta. The board of Vimta Labs Limited currently have 8 directors; the longest-serving is Harriman Vungal, appointed in 1990. 14 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Harriman Vungal DIN 00242621 | Whole-time director | 16 Nov 1990 | 35 yrs 11 mo | Vimta Labs Limited |
| Harita Vasireddi DIN 00242512 | Managing Director | 01 Apr 2005 | 21 yrs 6 mo | Vimta Labs Limited |
| Sivalinga Prasad Vasireddi DIN 00242288 | Whole-time director | 01 Apr 2005 | 21 yrs 6 mo | Vimta Labs Limited |
| Prameela Rani Yalamanchili DIN 03270909 | Director | 01 Dec 2017 | 8 yrs 10 mo | Vimta Labs Limited |
| Purnachandra Rao Gutta DIN 00876934 | Director | 11 May 2019 | 7 yrs 5 mo | Vimta Labs Limited |
| Sanjay Dave DIN 08450232 | Director | 11 May 2019 | 7 yrs 5 mo | Vimta Labs Limited |
| Satya Sreenivas Neerukonda DIN 00269814 | Whole-time director | 14 Jul 2019 | 7 yrs 3 mo | Vimta Labs Limited |
| Yadagiri R Pendri DIN 01966100 | Director | 10 Aug 2020 | 6 yrs 2 mo | Vimta Labs Limited |
People of Vimta
13 people are tracked at Vimta (6 in leadership, 5 in board & advisors, 2 in team); the tracked headcount is 1,310.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership | |
Suresh Kumar | President | Leadership |
Chandra Shekhar Sharma | VP Clinical Reference Lab | Leadership |
| Executive Director, Operations | Leadership | |
Janardhan Mergoju | VP Environment Services | Leadership |
Jagadeesh Kodali | Head, Food Division | Leadership |
Shri Gutta Purnachandra Rao | Additional Director | Board & advisors |
| Additional Director | Board & advisors | |
Smt Y Prameela Rani | Director | Board & advisors |
Shri Sanjay Dave | Additional Director | Board & advisors |
S P Vasireddi | Non-Executive Chairman | Board & advisors |
Upendra Bhatnagar | SVP, Preclinical | Team |
Sujani Vasireddi | Company Secretary | Team |
Complete people profiles for Vimta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Vimta
Vimta is a publicly listed company on the NSE with ticker symbol VIMTALABS in India, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Dec 2005
- Listed onNSE: VIMTALABS
- Listed entityVimta Labs Limited
- Exchange sectorCommercial services
- ISININE579C01029
- Share price₹540.85 (+1.74% on the day) · 2026-10-14
- Market capitalisation₹2,380 Cr
- Price to earnings30.6
- EPS (diluted, trailing year)₹17.66
- Dividend yield0.37%
- Volume (last session)55,701
Financials of Vimta
Figures of Vimta Labs Limited, the primary company behind Vimta, for FY 2026. Revenue was ₹416 Cr (+20% year on year). Net profit was ₹77.51 Cr (19% margin). EBITDA was ₹149 Cr (36% margin). Revenue has grown at a compounded annual rate of +9% over three years and +15% over five years.
- ₹416 CrRevenue · FY 2026 · +20% YoY
- ₹77.51 CrNet profit · 19% margin
- ₹149 CrEBITDA · 36% margin
- ₹8.93 CrPaid-up capital
- 1,456Employees (provident fund records)
- +9%Revenue CAGR, 3 years
- +15%Revenue CAGR, 5 years
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | ₹407 Cr | ₹77.5 Cr | ₹143 Cr |
| 2024 | ₹344 Cr | ₹67.3 Cr | ₹123 Cr |
| 2023 | ₹289 Cr | ₹41.0 Cr | ₹95.0 Cr |
| 2022 | ₹315 Cr | ₹48.2 Cr | ₹92.4 Cr |
| 2021 | ₹276 Cr | ₹41.3 Cr | ₹78.7 Cr |
Balance sheet, profit and loss, cash flow and ratios of Vimta Labs Limited are on its company page.
Detailed financial statements for Vimta
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Vimta
3 dated milestones of Vimta across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Vimta is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $17.0M.
Similar companies to Vimta
Vimta has 10 listed similar companies in our database, 7 of them funded. They include Charles River Laboratories, Cytel, LabCorp, Precision Medicine Group and Frontage Laboratories, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| criver.com | 1947 | Wilmington, United States | – | 21,400 | Provider of drug discovery and preclinical development services | |
| cytel.com | 1987 | Cambridge, United States | $2M | 509 | Data analysis and statistical solutions are provided for life sciences. | |
| labcorp.com | 1969 | Burlington, United States | – | 9,321 | Provider of laboratory tests for physicians | |
| precisionmedicinegrp.com | 2012 | Bethesda, United States | $257.21M | 2,151 | Provider of clinical research, development, and commercialization services for life sciences | |
| frontagelab.com | 2001 | Exton, United States | $10.24M | – | Early drug development services are provided for pharma firms. | |
| canopybiosciences.com | 2016 | St. Louis, United States | $4.48M | – | Cell line engineering services are offered via CRISPR-Cas9 technology. | |
| precisionformedicine.com | 2013 | Bethesda, United States | $150M | – | Company offering specialised R&D and clinical development services for the development of precision medicine based drugs and devices | |
| taimei.com | 2013 | Pleasanton, United States | $193.73M | – | A digital intelligence platform is focused on life sciences activities. | |
| scantox.com | 1977 | Lille Skensved, Denmark | – | 30 | Laboratory focused on providing pharmacology, toxicology, and histopathology services | |
| tenpointtherapeutics.com | 2020 | Cambridge, United Kingdom | $70M | – | Engineered cell-based therapeutics are developed to restore vision. |
Detailed similar companies of Vimta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Vimta
The website of Vimta (vimta.com) receives about 294.1K visits a month and ranks #145,084 among all websites worldwide, #4,447 in Biotechnology and Pharmaceuticals.
- Monthly visits294.1K
▼ 34.6% vs previous month
- Unique visitors34.3K
per month
- Global rank#145,084
among all websites
- Category rank#4,447
Health · Biotechnology and Pharmaceuticals
- Bounce rate5%
- Pages per visit4.4
- Average visit5 min 48 sec
- DevicesDesktop 2% · Mobile 98%
Websites whose visitors overlap most with Vimta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| synchronresearch.com | 100% | – | – | View details | |
| act-india.com | 99% | – | – | View details | |
jrfonline.com | jrfonline.com | 99% | – | – | – |
| ppccro.com | 99% | – | – | View details | |
cliniminds.com | cliniminds.com | 99% | – | #1,196,899 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Vimta
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as Vimta (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vimta
Complete news archive for Vimta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vimta
Vimta was founded in 1984 and raised its 1st funding round 22 years after it was founded.
Vimta is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Vimta has 1,310 employees.
The primary company behind Vimta, Vimta Labs Limited, reported revenue of ₹416 Cr for FY 2026, up 20% year on year.
Vimta Labs was founded in 1984 in Hyderabad, India, functioning as a contract research organization for pharmaceutical and biotechnology sectors. Analytical services, clinical research, preclinical studies, genomics, proteomics, and BABE testing are delivered to global clients. Operations involve 565 scientists working in chemistry, pharmacy, medicine, microbiology, molecular biology, and informatics.
Vimta's top competitors include LabCorp, Charles River Laboratories and Cytel.
Vimta offers cGMP Laboratory Service, Preclinical Research, Clinical Research, and Food Testing Services.
Yes, Vimta is publicly traded on NSE under the ticker symbol VIMTALABS.
Vimta operates through Vimta Labs Limited.
The legal entities of Vimta currently have 10 directors, including Purnachandra Rao Gutta, Sanjay Dave, Satya Sreenivas Neerukonda and others.
The website of Vimta receives about 294 thousand visits a month and ranks #145,084 among all websites worldwide.